

CSD/BSE&NSE/2025-26

July 19, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of the SEBI Listing Regulations, we would like to inform you that with respect to certain transactions related to ZCL Chemicals Limited (“ZCL”), which subsequently merged with erstwhile Cohance Lifesciences Limited (“**Erstwhile Cohance**”), and thereafter Erstwhile Cohance merged with the Company and the name of the Company was changed to Cohance Lifesciences Limited, and as already disclosed earlier in the abridged prospectus contained in the Notice of the NCLT convened Meeting of the equity shareholders for the merger of Erstwhile Cohance with the Company, the Department of Pharmaceuticals, Government of India had already granted a *post-facto* approval in 2022, and in furtherance of which the Company has now received an order dated July 18, 2025 (the “**Order**”) favorably disposing off the Erstwhile Cohance’s application for compounding.

We would like to clarify that Erstwhile Cohance was an unlisted entity which has now amalgamated with the Company and wound up, with effect from May 1, 2025, pursuant to the Scheme of Amalgamation of Erstwhile Cohance with and into the Company under Sections 230 to 232 of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder. Accordingly, the order has been issued in the name of the Company.

A compounding fee of Rs.8,29,88,900/- (Rupees eight crores twenty-nine lakhs eighty-eight thousand nine hundred only) is payable by the Company to the Reserve Bank of India, pursuant to the Order, which the Company intends to pay within the timelines prescribed in the Order.

The financial statements of Erstwhile Cohance for the year ended March 31, 2025 has already made provision for the above-mentioned compounding fee. There is no impact on financial, operation or other activities of the Company, quantifiable in monetary terms except to the extent of the compounding amount, pursuant to the Order, with respect to Erstwhile Cohance.

The details as required under SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith in Annexure.

We request you to take this information on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



Sl	Particulars	Details
a	Name of the Authority	Reserve Bank of India (“RBI”), Foreign Exchange Department, Mumbai
b	Nature and details of the action(s) taken, initiated or order(s) passed	<p>Prior to its merger with the Company, Erstwhile Cohance Lifesciences Limited (“Erstwhile Cohance”) had filed an application dated January 23, 2025 pursuant to the <i>post-facto</i> approval from the Department of Pharmaceuticals, Government of India.</p> <p>The compounding application was with respect to alleged violation of the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 in connection with certain foreign investments in ZCL Chemicals Limited (“ZCL”) in 2021, which was the predecessor to Erstwhile Cohance. ZCL merged with Erstwhile Cohance with effect from February 1, 2024.</p> <p>Subsequently, Erstwhile Cohance merged with the Company with effect from May 1, 2025 and the name of the Company was changed to its present name with effect from May 7, 2025.</p> <p>The compounding application was made by Erstwhile Cohance and upon the merger of the Erstwhile Cohance with the Company, the Company is the successor and has therefore received the compounding order whereby the Reserve Bank of India has approved the compounding against a payment of Rs.8,29,88,900/- (Rupees eight crores twenty-nine lakhs eighty-eight thousand nine hundred only) within 15 days from the date of the order.</p>
c	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	July 18, 2025
d	Details of the violations/contravention committed or alleged to be committed	<p>As stated above, the compounding application was with respect to alleged contravention of the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 with respect to foreign investment in ZCL, which subsequently merged with Erstwhile Cohance, and which merged with the Company.</p> <p>The compounding application was made by Erstwhile Cohance and upon the merger of the Erstwhile Cohance with the Company, the Company is the successor and has therefore received the compounding order whereby the Reserve Bank of India has approved the compounding against a payment of Rs.8,29,88,900/- (Rupees eight crores twenty-nine lakhs eighty-eight thousand nine hundred only) within 15 days from the date of the order.</p>
e	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The financial statements of Erstwhile Cohance for the year ended March 31, 2025 has already made provision for the above-mentioned compounding fee. There is no impact on financial, operation or other activities of the Company, quantifiable in monetary terms except to the extent of the compounding amount.

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.

Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.

Tel: +91 22 6153 9999

